Your browser doesn't support javascript.
loading
Application of lenalidomide in chronic lymphocytic leukemia / 中国实验血液学杂志
Journal of Experimental Hematology ; (6): 565-568, 2014.
Article in Chinese | WPRIM | ID: wpr-349669
ABSTRACT
In recent years, the incidence of chronic lymphocytic leukemia (CLL) is increasing. Microenvironment and immune system play a key role in the pathogenesis of CLL. The immune system is aggravated by the use of chemotherapeutic agents, such as fludarabine and cyclophosphamide with rituximab(FCR) which are the current standards in frontline therapy. This leads to an increase of infection incidence in patients, resulting in a poor prognosis. The present situation was changed by lenalidomide. Recent studies indicated that lenalidomide monotherapy in treatment of refractory or relapsed CLL patients, the overall response rate(ORR) reached about 32%-47%, CR roughly was 7%-13%; when lenalidomide and rituximab were combined for treatment of refractory or relapsed CLL patients, the ORR reached about 53%-66%, CR about 12%-13%. Moreover, when lenalidomide and ofatumumab were combined, the efficacy is improved significantly and the adverse reactions are greatly reduced. The adverse reactions are neutrophilic granulocytopenia, thrombocytopenia, anemia, tumor lysis syndrome(TLS), tumor flare reaction(TFR) and venous thromboembolism(VTE). This review focuses on the related studies and the latest progress about lenalidomide in CLL.
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Thalidomide / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Therapeutic Uses / Drug Therapy Type of study: Practice guideline / Prognostic study Limits: Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2014 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Thalidomide / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Angiogenesis Inhibitors / Therapeutic Uses / Drug Therapy Type of study: Practice guideline / Prognostic study Limits: Humans Language: Chinese Journal: Journal of Experimental Hematology Year: 2014 Type: Article